Keeping Track: Novel Oncologics Submitted By Taiho, ImmunoGen, Y-mAbs; US FDA Declines Akebia’s Vadadustat

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

A trio of novel cancer agent applications announced last week illustrates the breadth of oncology R&D, from targeted kinase inhibitors (Taiho Pharmaceutical Co. Ltd.’s futibatinib) to antibody-drug conjugates (ImmunoGen, Inc.’s mirvetuximab soravtansine) and radioimmunotherapy (Y-mAbs Therapeutics Inc.’s 131I-omburtamab).

Other recently submitted products aim to shake up established spaces. Outlook Therapeutics, Inc. plans to take on the widespread use of compounded and repackaged IV bevacizumab for ophthalmic use with Lytenava, its intravitreal formulation of the angiogenesis inhibitor. CorMedix Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By 

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.